Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  New England Journal of Medicine

• Publication date

  2010-09-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMra0912063PMID 20879883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.

  2010cited by this paper
• World J Gastroenterol

  2010cited by this paper
• Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients.

  2009cited by this paper
• Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population.

  2009cited by this paper
• Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma‐glutamyl transpeptidase levels

  2009cited by this paper
• Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.

  2009cited by this paper
• Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome.

  2009cited by this paper
• Long-term follow-up of patients with nonalcoholic fatty liver.

  2009cited by this paper
• Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans.

  2009cited by this paper
• Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

  2008cited by this paper
• NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men

  2008cited by this paper
• Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.

  2008cited by this paper
• A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin Resistance

  2008cited by this paper
• Insulin resistance, inflammation, and non-alcoholic fatty liver disease.

  2008cited by this paper
• Obesity-associated liver disease.

  2008cited by this paper
• Causes and metabolic consequences of Fatty liver.

  2008cited by this paper
• Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.

  2008cited by this paper
• Carotid artery intima-media thickness in nonalcoholic fatty liver disease.

  2008cited by this paper
• Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis

  2008cited by this paper
• Non-alcoholic fatty liver disease: the mist gradually clears.

  2008cited by this paper
• Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study

  2008cited by this paper
• The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes.

  2008cited by this paper
• Hepatic Steatosis and Subclinical Cardiovascular Disease in a Cohort Enriched for Type 2 Diabetes: The Diabetes Heart Study

  2008cited by this paper
• Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review.

  2008cited by this paper
• Gamma-Glutamyltransferase Is Associated With Incident Vascular Events Independently of Alcohol Intake: Analysis of the British Women’s Heart and Health Study and Meta-Analysis

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.

  2007cited by this paper
• The adipocyte as an active participant in energy balance and metabolism.

  2007cited by this paper
• Postprandial lipemia associates with liver fat content.

  2007cited by this paper
• Obesity, inflammation, and insulin resistance.

  2007cited by this paper
• Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

  2007cited by this paper
• Benefits of lifestyle modification in NAFLD

  2007cited by this paper
• Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver

  2007cited by this paper
• Inaugural Article: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome

  2007cited by this paper
• Fatty Liver: A Novel Component of the Metabolic Syndrome

  2007cited by this paper
• Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk: The Framingham Heart Study

  2007cited by this paper
• High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH

  2007cited by this paper
• Liver: an alarm for the heart?

  2007cited by this paper
• Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C.

  2007cited by this paper
• Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Disordered lipid metabolism and the pathogenesis of insulin resistance.

  2007cited by this paper
• The metabolic syndrome and cardiovascular disease

  2006cited by this paper
• Cardiac Abnormalities as a New Manifestation of Nonalcoholic Fatty Liver Disease: Echocardiographic and Tissue Doppler Imaging Assessment

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

  2006cited by this paper
• Inflammation and insulin resistance.

  2006cited by this paper
• Statins and hepatic steatosis: Perspectives from the Dallas Heart Study

  2006cited by this paper
• Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes.

  2006cited by this paper
• Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women.

  2006cited by this paper
• From fat to inflammation.

  2006cited by this paper
• Sonographic fatty liver, overweight and ischemic heart disease.

  2005cited by this paper
• Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

  2005cited by this paper
• Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.

  2005cited by this paper
• The development of a comorbidity index with physical function as the outcome.

  2005cited by this paper
• Nonalcoholic fatty liver disease

  2005cited by this paper
• Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease

  2005cited by this paper
• Hepatic steatosis is associated with an increased risk of carotid atherosclerosis.

  2005cited by this paper
• Histopathology of pediatric nonalcoholic fatty liver disease

  2005cited by this paper
• Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study

  2005cited by this paper
• The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

  2005cited by this paper
• Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.

  2005cited by this paper
• Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation.

  2004cited by this paper
• Long term prognosis of fatty liver: risk of chronic liver disease and death

  2004cited by this paper
• Metabolic Syndrome and Cardiovascular Disease

  2003cited by this paper
• Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis

  2003cited by this paper
• Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

  2003cited by this paper
• Toll-like receptor 4 polymorphisms and atherogenesis.

  2002cited by this paper
• Toll-like receptor 4 polymorphisms and atherogenesis.

  2002cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• Nonalcoholic fatty liver disease.

  1986cited by this paper

• α-Parvin promotes glucose uptake and metabolism in skeletal muscle with minimal influence on hepatic insulin sensitivity

  2026cites this paper
• Metabolic Liver Disease Beyond the Liver

  2026cites this paper
• Cardiovascular Risk in MASLD: What Multiple Lines of Evidence Reveal.

  2026cites this paper
• Comparative risk of postoperative complications after total shoulder arthroplasty in patients with non-alcoholic cirrhosis versus NAFLD: A matched national cohort study.

  2026cites this paper
• Obesity as a predictor of atherogenic dyslipidemia in patients with metabolic dysfunction associated steatotic liver disease

  2026cites this paper
• Association of the Triglyceride-Glucose Index With Established Cardiovascular Disease in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study

  2026cites this paper
• Mapping sex-based multimorbidity networks in type 1 diabetes: a real-world study from Shanghai.

  2026cites this paper
• miR-125b-5p regulates FFA-induced hepatic steatosis in L02 cells by targeting estrogen-related receptor alpha.

  2025cites this paper
• Association Between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Short-Term Progression of Carotid Atherosclerosis Among Early Middle Age Adults

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations

  2025cites this paper
• Features of the development and treatment of lipid metabolism disorders in patients with metabolic dysfunction-associated steatotic liver disease: A review

  2025cites this paper
• Ketogenic diets and metabolic dysfunction-associated steatotic liver disease: a literature review

  2025cites this paper
• The use of simple tests to predict biopsy-proven steatohepatitis in people with type 2 diabetes

  2025cites this paper
• Effect of Testosterone Therapy (TTh) on Liver Function and Steatosis

  2025influential citation
• Hepatic steatosis associates with leukopoietic activity and atherosclerotic inflammation: mechanistic insights into cardiovascular risk.

  2025cites this paper
• Skeletal Muscle and Cardiovascular Health.

  2025cites this paper
• Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways

  2025cites this paper
• Relationship between level of serum VIT D and insulin resistance in patients with MAFLD

  2025cites this paper
• Elimination of hepatocyte‐derived DPP4 downregulates cardiac immune‐ and collagen‐related genes but does not alter cardiac function in aged male mice

  2025cites this paper
• R-spondin 2 suppresses hepatic steatosis via activation of AMPK-ACC signaling

  2025cites this paper
• Does age at menarche influence final height in female adolescents?

  2025cites this paper
• Association between urinary albumin-to-creatinine ratio and metabolic dysfunction-associated fatty liver disease in individuals without diabetes mellitus

  2025cites this paper
• Association between serum uric acid to creatinine ratio with metabolic profile in subjects with non-alcoholic fatty liver disease (NAFLD)

  2025cites this paper
• Increased Risk of Postoperative Complications in Non-Alcoholic Cirrhosis Versus Non-Alcoholic Fatty Liver Disease Following Total Knee Arthroplasty: A National Matched Cohort Study.

  2025cites this paper
• Association of steatotic liver disease with all-cause and cardiovascular mortality among prehypertensive or hypertensive patients

  2025cites this paper
• Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis

  2025cites this paper
• Cardiovascular Manifestations of Patients with Non-Alcoholic Fatty Liver Disease

  2025influential citation
• Association between visceral adiposity index and all-cause and cardiovascular mortality in the non-elderly adults

  2025cites this paper
• Fetuin-A increases thrombosis risk in non-alcoholic fatty liver disease by binding to TLR-4 on platelets.

  2025cites this paper
• Relationship of fat in the pancreas with cardiovascular disease: A systematic review and meta‐analysis

  2025cites this paper
• Extrahepatic manifestations of metabolic dysfunction-associated steatotic liver disease: An updated clinical overview

  2025cites this paper
• Adenosine deaminase and interleukin-1 receptor antagonist genetic polymorphisms among obese children with versus without metabolic dysfunction-associated fatty liver disease

  2025cites this paper
• Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study.

  2025cites this paper
• Impact of Lipid-Lowering Medications on Cardiovascular Outcomes and Lipid Profiles in NAFLD/NASH Patients: A 5-Year Retrospective Cohort Study.

  2025cites this paper
• Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis.

  2025cites this paper
• Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders

  2025cites this paper
• Chalcone derivative 1m mitigates hepatic fibrosis and inflammation, enhances cholesterol efflux and reduces atherosclerosis.

  2025cites this paper
• Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on Atrial Fibrillation Recurrence After Ablation　- A Retrospective Study in Japanese Patients.

  2025cites this paper
• Research progress of epidermal growth factor receptor in metabolic dysfunction‐associated steatotic liver disease and related diseases

  2025cites this paper
• Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis

  2025cites this paper
• Association between metabolic dysfunction-associated steatotic liver disease and cardiovascular disease: New perspectives

  2025influential citation
• Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

  2025cites this paper
• 27-Hydroxycholesterol exacerbates hepatic insulin resistance via plasma membrane cholesterol remodeling.

  2025cites this paper
• Retrospective Database Analysis of the Clinical and Economic Outcomes Associated with Disruptive Surgical Bleeding

  2025cites this paper
• Establishment of sex-specific liver transcriptomes and H3K9me3 profiles during sexual maturity: the impact of maternal obesity

  2025cites this paper
• Die Metabolismus-assoziierte Lebererkrankung (MASLD)

  2025cites this paper
• Cardiac‐Focused Multi‐Organ Chips: Advanced Disease Modeling, Drug Testing, and Inter‐Organ Communication

  2025cites this paper
• Platelet Thromboxane B2 overproduction associated with liver fibrosis severity in patients with MASLD.

  2025cites this paper
• Predictive Value of Liver Fibrosis Index-4 for Clinical Outcomes Following Carotid Artery Stenting.

  2025cites this paper
• Genetic risk factors for MASLD/MASH and cardiovascular disease in elderly individuals.

  2025cites this paper
• Liver Fibrosis and Cardiovascular Events

  2025cites this paper
• Association between Noninvasive Liver Biomarkers and Graft Outcomes in Kidney Transplantation Recipients

  2025cites this paper
• Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review

  2025cites this paper
• Serum 25(OH)D Levels and Risk of Nonalcoholic Fatty Liver Disease in Nonobese and Lean Individuals

  2025cites this paper
• Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure.

  2025cites this paper
• Stratified Burden of MASLD in Cardiovascular Kidney Metabolic syndrome: Stage-Dependent Prevalence and Insulin Resistance-Driven Cardiovascular Mortality

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease as a predictor of cognitive performance: An 11-year population-based follow-up study.

  2025cites this paper
• Cardiovascular events and incident diabetes in 220 patients with MASLD according to basal liver fibrosis: a 10-year follow-up historic cohort

  2025cites this paper
• A strategy for liver selective NRF2 induction via cytochrome P450-activated prodrugs with low activity in hypoxia

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease as a Cardiovascular Risk Factor: Focus on Atrial Fibrillation.

  2025cites this paper
• Hepatic steatosis is associated with impaired hepatic glucose uptake under hyperglycemic conditions, a dynamic whole-body 18F-FDG PET approach.

  2025cites this paper
• The efficacy of DASH combined with time-restricted feeding (16/8) on metabolic associated fatty liver disease management: a randomized controlled trial

  2025cites this paper
• Die Metabolismus-assoziierte Lebererkrankung (MASLD)

  2025cites this paper
• eHealth interventions and patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

  2025cites this paper
• Prognostic Significance of Fatty Liver Index for the Development of Hypertension and Cardiovascular Events in Populations With Suboptimal Blood Pressure

  2025cites this paper
• Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a predictor of all cause and cardiovascular mortality in United States adults with NAFLD: a prospective cohort study

  2025cites this paper
• Association Between High Sensitivity Cardiac Troponin and All-Cause and Cardiovascular Mortality in Adults at Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study

  2025cites this paper
• The role of mean platelet volume in metabolic dysfunction associated steatotic liver disease

  2025cites this paper
• Genome-wide enhancer-gene regulatory maps of liver reveal novel regulatory mechanisms underlying NAFLD pathogenesis

  2025cites this paper
• Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.

  2025cites this paper
• Insights for lncH19, miR-9, and miR-146a expression levels and their cross-talk with pro-inflammatory cytokines, copeptin, and neopterin profile in type 1 diabetic cardiomyopathy

  2025cites this paper
• Role of visceral adiposity in the relationship between cardiorespiratory fitness and liver fat in asymptomatic adults.

  2025cites this paper
• Gut Microbiota and Liver Health: Meta-Analysis of Bifidobacterium-Containing Probiotics in NAFLD Management

  2025cites this paper
• The Interplay of Cardiometabolic Syndrome Phenotypes and Cardiovascular Risk Indices in Patients Diagnosed with Diabetes Mellitus

  2025cites this paper
• Mean Corpuscular Volume Is Correlated with Liver Fibrosis Defined by Noninvasive Blood Biochemical Indices in Individuals with Metabolic Disorders Aged 60 Years or Older

  2025cites this paper
• Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study

  2025cites this paper
• Associations among serum FGF21 levels, inflammation, and metabolic dysfunction-associated steatotic liver disease: mediation analyses in a Chinese community-based population

  2025cites this paper
• Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD

  2025cites this paper
• Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD

  2025cites this paper
• Identification of biomarkers between coronary artery disease and non-alcoholic steatohepatitis: a combination of bioinformatics and machine learning

  2025cites this paper
• Alginate/derivatives and their nanoparticles as anti-diabetic therapeutic via cancer, gut, liver and blood health modulation: A review.

  2025cites this paper
• Impact of metabolic dysfunction-associated fatty liver disease on left ventricular function and myocardial strain in patients with ASTEMI: Insights from a 3.0-T cardiac magnetic resonance study.

  2025cites this paper
• Postoperative Complication Risk Following Carpometacarpal Arthroplasty in Patients with Non-Alcoholic Fatty Liver Disease Versus Non-Alcoholic Cirrhosis: A Matched Cohort Study

  2025cites this paper
• Association between questionnaire- and accelerometer-measured physical activity and incidence of cardiovascular disease in subjects with metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Impact of smoking and physical activity on cardiovascular outcomes in type 2 diabetes across steatotic liver disease categories

  2025cites this paper
• Body muscle mass versus fat mass: gender-specific associations with NAFLD and liver fibrosis

  2025cites this paper
• Visiting MASLD through the lens of sex, immunity, and microbial interactions

  2025cites this paper
• α-Parvin Promotes Glucose Uptake and Metabolism in Skeletal Muscle with Minimal Influence on Hepatic Insulin Sensitivity

  2025cites this paper
• Contrastive Learned Self-Supervised Technique for Fatty Liver and Chronic Liver Identification

  2025cites this paper
• The association of steatotic liver disease with cardiometabolic criteria and cardiovascular disease risk in a large cohort of people living with human immunodeficiency virus

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease.

  2025cites this paper
• Differentiating MASL and MASH: Clinical Insights from Comparative Case Reports in MASLD

  2025influential citation
• Impact of statins on liver transaminases in patients with metabolic dysfunction–associated steatotic liver disease: A 12-month retrospective review

  2025cites this paper
• Association of metabolic dysfunction–associated fatty liver disease with coronary CT angiography-derived plaque characteristics and cardiovascular events

  2025cites this paper
• Cardiovascular Health Trajectories and Prevalent Metabolic Dysfunction‐Associated Steatotic Liver Disease in Midlife: The CARDIA Study

  2025cites this paper
• The Basics of Metabolic Dysfunction-Associated Steatotic Liver Disease for Cardiologists: Pathophysiology, Diagnosis, and Treatment.

  2025cites this paper
• Obesity and Metabolic Syndrome in the 21st Century: A Narrative Review of Cardiometabolic Risk and Global Policy Response

  2025cites this paper
• When the Liver Echoes to the Heart: Assessing Subclinical Cardiac Dysfunction in NAFLD Using Speckle Tracking Echocardiography—A Systematic Review and Meta-Analysis

  2025cites this paper
• Relationship Between Liver Fibrosis and Increased Risk of Symptomatic Intracranial Hemorrhage in Ischemic Stroke Patients Undergoing Mechanical Thrombectomy

  2024cites this paper